Why Didn't Pfizer and BioNTech Stocks Soar After Their COVID Vaccine Achieved 100% Efficacy in Kids?

By newsfeedback@fool.com (Keith Speights)5 days ago

AD

We've known for a while that the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) was highly effective in individuals ages 16 and up. The two partners recently announced an impressive 100% efficacy for the vaccine in children between the ages of 12 and 15.In this Motley Fool Live video recorded on March 31, Motley Fool contributors Keith Speights and Brian Orelli discuss why neither of these stocks soared after the news about this great efficacy in kids.

Keith Speights: Pfizer and BioNTech announced results from their phase 3 study and this study showed 100% efficacy for their COVID vaccine, BNT162b2. Kids ages 12 through 15. So the companies plan to move pretty quickly to file for Emergency Use Authorization.

So last I looked, I'm going to check really quick here, Brian. So BioNTech stock is up around 5%. It's actually up just a little under 5% right now. Pfizer stock is up all of 0.4%. At one point this morning, it was even down a little bit.

Brian, I'm sure investors might be wondering, with this great news, why do you think these two stocks didn't jump even more?

Brian Orelli: It makes sense that BioNTech would move more than Pfizer because it's a lot smaller, so it's a lot more dependent on this one vaccine. It's literally the company's only drug at this point, although some of their valuation is built on their pipeline. Potentially it's already priced in.

Continue read on fool.com